摘要
摘要
OBJECTIVE: This study aimed to explore the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who had a history of systemic therapies. METHODS: Data were derived from a phase III trial (NCT04839016). This post hoc analysis included patients with moderate-to-severe plaque psoriasis who had a history of systemic therapies, including non-biological systemic therapies (N = 307), biological therapies (N = 32), or both (N = 10), totaling 329 unique patients. Patients were assigned to the vunakizumab (N = 210) and placebo (N = 119) groups according to the treatment regimens. RESULTS: The proportions of patients achieving week (W) 12 Psoriasis Area and Severity Index (PASI) 75, PASI 90, PASI 100, and static Physician's Global Assessment score of 0 or 1 (sPGA 0/1) responses were higher in the vunakizumab group than in the placebo group (all P > 0.001). These trends were found at most time points over 52 weeks. The median time to achieve PASI 75/90/100 response was 4.4, 8.3, and 16.3 weeks after vunakizumab treatment. Regarding patient-reported outcomes, at W4, W8, and W12, mean Dermatology Life Quality Index (DLQI) and itch numerical rating scale scores were lower, while the proportion of patients achieving DLQI 0/1 response was higher in the vunakizumab group than in the placebo group (P < 0.05). The incidence of any adverse event during the induction period or the entire treatment period was not different between the two groups (P > 0.05). CONCLUSION: Vunakizumab has better efficacy than placebo with satisfactory safety profiles in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies.
KM 提取结果
0 个 Figure · 0 个 KM 面板